Stifel Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $47

Benzinga · 10/08 11:51
Stifel analyst Stephen Willey initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $47.